New online platform aims to help young adults navigate genetic cancer risks

NCT ID NCT05759143

Recruiting now Knowledge-focused Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new online platform called Nest for young adults aged 18-39 who have had genetic testing for cancer risk. The platform gives both patients and their doctors access to updated information about genetic findings. Researchers want to see if the tool is easy to use and if it helps people better understand their cancer risk and follow recommended screening.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nest platform (online portal for patients and clinicians)
What this could lead to: If successful, this platform could help young adults better understand and act on their genetic cancer risk results, leading to more appropriate screening and follow-up care.
What could go wrong: This is a small, early feasibility study with only 40 participants, so results may not apply to everyone. The platform may not improve knowledge or screening as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENETIC PREDISPOSITION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inherited disease susceptibility

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENETIC PREDISPOSITION GENETIC PREDISPOSITION TO DISEASE

Contacts and locations

Locations

Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.